Skip to content

Surgical Approach for Retrorectal Tumors Cohort

Surgical Approach for Retro-rectal Tumors: a Retrospective Bicentric Cohort (SART Cohort)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04757103
Acronym
SART cohort
Enrollment
21
Registered
2021-02-17
Start date
2021-01-01
Completion date
2021-05-01
Last updated
2021-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Tumor

Keywords

Retrorectal tumor, Tail gut cyst, Benign tumor, Mini-invasive approach, Open approach, Perineal approach

Brief summary

Aim of the study : To evaluate postoperative outcomes of all surgical approach for retrorectal tumors. Methods : From 2005 to 2020, all consecutive patients who underwent surgery for a retrorectal tumor in two referral tertiary center were prospectively collected. Considering our exlusion criterias, data from XX patients were analyzed. The cohort was separated into 2 groups according to tumor localization regarding the third sacral vertebra. Short and longterm outcomes were compared between the two groups. Primary outcome : 90 days postoperative morbidity rate

Detailed description

Retro-rectal tumors are a group of heterogeneous and rare lesions. The actual incidence has been estimated to be approximately one case per 40,000 admissions. It is most often a benign tumor that affects young women and the origin is congenital in 60% of cases. The most common benign lesion is a tailgut cyst. Chordoma is the most common malignant lesion. They are mostly asymptomatic or pauci-symptomatic. This is why their diagnosis is regularly accidentaly after a morphological examination such as an abdominal ultrasound or a CT scan. MRI is the gold standard for determining the structure of the lesion, its origin, its topography, its extension in relation to adjacent organs, parameters that are essential to define the type of surgery and its approach. When a retro-rectal tumor is diagnosed, the standard treatment is surgical resection. A biopsy is not helpful if there is no suspicion of a degenerate lesion. Usually, lesions located under the third sacral vertebra (S3) are approached by dorsal transsacrococcygeal, perineal or combined approach (abdominal and perineal approach) while those located above S3 the approach is abdominal (laparotomy or laparoscopy). As these lesions are, in the majority of cases, benign, the functional impact of surgery is essential. Based on our experience in minimally invasive surgery and in particular in retro-rectal tumors, laparoscopy has become our first-line approach regardless of the location of the lesion compared to S3. Our hypothesis is that the minimally invasive approach is reliable, safe and allows satisfactory histological results to be obtained while limiting postoperative pain and functional sequelae.

Interventions

PROCEDUREResection of the retrorectal tumor

Surgical resection of the retrorectal mass

Sponsors

Université Montpellier
CollaboratorOTHER
Centre Hospitalier Universitaire de Nīmes
CollaboratorOTHER
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* Patient presenting a retrorectal tumor * Surgical procedure between 01/01/2005 and 31/12/2020

Exclusion criteria

* age \< 18 years old * Patients presenting a rectal tumor * Patients presenting a rectal duplication

Design outcomes

Primary

MeasureTime frameDescription
Postoperative morbidity rate90 daysPostoperative morbidity according to Clavien Dindo

Secondary

MeasureTime frameDescription
Reoperation rate90 daysAny reoperation linked to surgical resection of the retrorectal tumor
Quality of surgical resection90 daysEvaluation of surgical margins according to pathological examination
Mortality rate90 daysMortality rate
Rate of functional outcomes90 daysEvaluation of fecal
Functional outcomes90 daysEvaluation of sexual functions
Conversion to open approach90 daysConversion to laparotomy in case of mini-invasive approach

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026